[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 15, 1965

Advances in Cardiology

JAMA. 1965;191(11):33-42. doi:10.1001/jama.1965.03080110101061

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


A study of 148 patients who suffered attacks of cerebral thrombosis shows that in females there was a highly significant probability of increased survival due to estrogen therapy.

Estrogen therapy showed no beneficial effect in men, however.

Preliminary results of the study were reported by Roger W. Robinson, MD, chief of the Medical Division, Worcester Memorial Hospital, Mass.

Patients with cerebral thrombosis were selected for the prospective study from the Medical Division of the Memorial Hospital. The group has been observed since 1957.

Patients were assigned to the control or estrogen therapy group by random selection.

The male patients in the estrogen therapy group were given 5 mg of oral diethylstilbestrol daily. The standard dose for the female patients was 15 mg daily.

"Studies in our laboratory have shown that a daily dose of 5 mg of stilbestrol in men not only produced optimal serum lipid effects, but also produced

First Page Preview View Large
First page PDF preview
First page PDF preview